SUMMARY Menstrually related temporary remissions of myasthenic symptoms are reported to occur in 25 to 50% of female patients. Even though this has been attributed to hormonal changes associated with the menstrual cycle the underlying mechanism of this hormonal influence has remained elusive. The present study demonstrated a cyclical variation in the activity of red cell acetylcholinesterase (EC 3.1.1.7) enzyme (AChE) with a marked reduction at the time of menstrual remission of symptoms of myasthenia. These cyclical changes were abolished by thymectomy. It appears, therefore, that menstrual remission in myasthenia is at least partly due to hormone-induced changes in AChE activity. This process seems to be under the control of the thymus gland.
Blood samples were collected in heparinised tubes with adequate precautions to avoid haemolysis. Red cells and serum were separated in a clinical centrifuge immediately after collection of the blood. Cells were washed three times with normal saline to remove all serum. Assaying of the red cell samples for serum cholinesterase (EC 3.1.1.8) helped to confirm that there was no serum contamination after this washing procedure. The washed red cells were haemolysed with 1.0 volume of distilled water and 0.4 volume of toluene. Red cell membranes were extracted twice after vigorous shaking and centrifugation at 6000 g for 20 minutes in a Sorvall refrigerated centrifuge. The cell membrane preparation was then resuspended to the original volume in 5% Triton X-100 in 0.01 M phosphate buffer at pH 7.4. This preparation was used for assay either immediately or after storage at -10°C (Coates and Simpson, 1972 
Results
The data were analysed using the regressive analysis programmes BMDOIR and BMDO5R of the biomedical statistical package programmes. As expected from the small number of cases, most of the information was expressed by first degree regression. AChE levels during three menstrual cycles in the myasthenic patients and control subjects were fairly reproducible for each individual (Fig. 1) . In the myasthenic patients there was a progressive increase in enzyme activity from the end of one menstrual cycle to the beginning of the next, when there was a rapid reduction in myasthenic patients the enzyme activity rose rapidly. Roughly halfway through the cycle, the enzyme levels increased above controls and continued to rise until the beginning of menstrual flow. The overall activity changed from 0.02 to 0.071 AA/min in the myasthenics, compared to 0.052 to 0.066 AA/min* in controls. Myasthenic patients without menstrual remission of symptoms did not show this cyclical variation and resembled the normal controls.
These cyclical changes in AChE activity correlated well with the medication requirements (Fig. 3) . This represents a single cycle in patient 1, studied three months after thymectomy when the medication requirements had already diminished but the patient still experienced the cyclical variations, though to a lesser extent. the activity. This cyclical change in enzyme activity was minimal in control subjects when compared with the patients. In the quadratic regression curves (Fig. 2 ) the regression slopes of controls and myasthenic patients were significantly different (F ratio of 383.9 for 1.168 degrees of freedom). The control subjects showed almost straightline activity of the enzyme, with very little variation from the beginning to the end of the cycle. In myasthenic patients, the activity started at a lower level than controls, probably related to anticholinesterase medication. As the cycle progressed, however, in Discussion Menstrual influence on myasthenia gravis has been generally believed to be unpredictable or variable. Collins, in 1897, was the first to document menstrually related changes in myasthenic symptoms. Since then, detailed clinical observations of a similar nature have been reported by others (Adam, 1946; Keynes, 1952; Osserman, *AA/min =delta absorbance/minute. It can be converted into SI units by a conversion factor calculated for the extinction coefficient of the reaction product (1.36 x 104) and the red cell count of the sample (see Ellman et al., 1961) . 1958). A review of these cases indicates that 34-50% of these patients had deterioration of symptoms a few days before the onset of menstrual periods and subsequent improvement with the beginning of menstrual flow. This is very similar to the cyclical deterioration and improvement noted in three of 12 patients seen in our clinic. It is reasonable to believe that the menstrual improvement of symptoms is related in some way to hormonal changes occurring during menstruation. However, to date, the mechanism underlying this type of hormonally related remission has remained elusive. The mechanism of action of gonadal secretion on target organs, including skeletal muscles, has been the subject of numerous studies (Mueller et al., 1972; Massa et al., 1975) . DATE muscle structure and function, and, therefore, cannot be held responsible for the cyclical and rapidly occurring functional alterations seen in the myasthenic patients.
II
Another probably relevant observation is the 'blocking action' of progesterone on uterine contractions (Csapo, 1956 (Csapo, , 1973 . Maintenance of pregnancy is dependent upon the endogenous and placental progesterone which inhibits the contraction of the myometrium. The actual mechanism which maintains this blocking action is still unknown. If such a blocking action also involves skeletal muscles, the menstrual remissions seen here could be attributed to progesterone withdrawal.
A possible effect of oestrogens on cholinergic metabolism may also explain this relationship. There have been only a few studies dealing with this aspect of the problem, examining the influence of hormones on muscle contraction or on acetylcholine metabolism (Reynolds and Foster, 1939; Torda, 1943; Barnes and Epperson, 1952) . Hormonal influence on acetylcholine metabolism has been determined by assaying the activity of cholinesterases in the blood. The results of these earlier studies have been inconclusive. Moreover, they are difficult to interpret since all forms of esterases, not AChE specifically, were estimated simultaneously without the use of specific inhibitors. Inhibitors were not available at that time or were not used. However, more recent animal observations have shown that sex hormones do influence the activity of various esterases (Wooley, 1963; Augustinsson and Henricson, 1970) . It has also been shown that in the immature and adult animals, AChE activity in the central nervous system can be increased by the administration of oestrogens (Moudgil and Kanungo, 1973) .
Results of the present study demonstrate that there is an exaggerated cyclical variation in red cell AChE activity in some myasthenic patients which correlates well with the remission of symptoms during a menstrual cycle. The progressive increase in the activity of the red cell AChE observed in this study seems to go hand in hand with the increasing secretion of oestrogens as the menstrual cycle progresses. Then as the menstrual flow begins there is a sudden drop in the enzyme activity. Progesterone levels also follow a pattern similar to that of oestrogen during the latter half of the cycle and may have a similar influence on AChE activity. However, much less is known about the effects of progesterone on AChE. Some studies have indicated an abnormal progesterone metabolism in myasthenics (Schrire, 1959 (Foldes and Smith, 1966 remissions. It seems to be dependent also on thymic activity. Keynes (1952) reported that his myasthenic patients ceased to have the menstrual variations after thymectomy. A similar change was observed in both of our patients who underwent thymectomy. The thymus is known to have its own endocrine regulatory functions, and it has been well established that this organ controls the activity of a number of endocrine glands, including the gonads (Luckey, 1973) . The thymus has recently been reported to play a role in female sexual maturation (Basedovsky and Sorkin, 1974 
